UNA oligomer structures for therapeutic agents

Patent metadata

Field	Value
Publication number	US-9340789-B2
Application number	US-200913130032-A
Country	US
Kind code	B2
Filing date	Dec 3, 2009
Priority date	Dec 3, 2008
Publication date	May 17, 2016
Grant date	May 17, 2016

Abstract

This disclosure provides double-stranded RNA complexes having one or more hydroxymethyl substituted nucleomonomer(s) in the passenger strand (or sense strand) of an RNA complex. RNA complexes of the disclosure may be useful for therapeutic applications, diagnostic applications or research applications. RNA complexes include short interfering RNA complexes (siRNA) capable of modulating gene expression comprising an antisense strand and a continuous or a discontinuous passenger strand (“sense strand”). Further, one or more hydroxymethyl substituted nucleomonomer(s) of this disclosure may be positioned at the 3′-end, at the 5′-end, at both the 3′-end and 5′end.

First claim

The invention claimed is:

1. An oligomeric compound comprising one or more acyclic 2′-3′-seco-monomers and one or more ribonucleic acid monomers, the oligomeric compound comprising a sense strand and an antisense strand that together form only one double-stranded region of 15 to 24 base pairs, wherein the 5′-terminal monomer of the sense strand is a terminus of the double-stranded region, wherein any one or more of the two positions at the 5′-end of the sense strand is occupied by the same or different acyclic 2′-3′-seco-monomer, wherein the oligomeric compound has at least one 3′-overhang, and wherein the oligomeric compound is active in RNA interference to modulate expression of a targeted mRNA.

2. The oligomer of claim 1 , further comprising that one or both of the last two positions of the 3′-end of the antisense strand is occupied by the same or different acyclic 2′-3′-seco-monomer.

3. The oligomeric compound of claim 1 , wherein the double-stranded region has 19 or 20 base pairs.

4. The oligomeric compound of claim 1 , wherein the sense strand and the antisense strand are each 21 or 22 nucleomonomers in length.

5. The oligomeric compound of claim 1 , wherein the oligomeric compound has a blunt end.

6. The oligomeric compound of claim 1 , wherein the antisense strand has a region of at least 15 contiguous nucleomonomers corresponding to any 15 contiguous nucleomonomers of SEQ ID NOs: 12, 34, 56, 78, 100, 124, or 147.

7. The oligomeric compound of claim 1 , wherein the acyclic 2′-3′-seco-monomer is selected from the group of monomers D, F, G, H, I, and J:

wherein R is selected from the group consisting of a hydrogen, an alkyl group, a cholesterol derivative, a fluorophore, a polyamine, a fatty acid, an amino acid, a saccharide and a polypeptide
wherein Base is any purine, pyrimidine, or derivative or analogue thereof.

8. The oligomeric compound of claim 1 , further comprising a nucleotide analogue selected from the group consisting of 2′-O-alkyl-RNA monomers, 2′-amino-DNA monomers, 2′-fluoro-DNA monomers, PNA monomers, HNA monomers, ANA monomers, FANA monomers, CeNA monomers, ENA monomers, DNA monomers, and INA monomers.

9. A method for reducing expression of a gene in a cell comprising preparing an oligomeric compound of claim 1 and treating the cell with the oligomeric compound.

Assignees

• Templin Michael V
• Vaish Narendra K
• Polisky Barry A
• Houston Jr Michael E
• Arcturus Therapeutics Inc

Inventors

• Templin Michael V
• Vaish Narendra K
• Polisky Barry A
• Houston Jr Michael E

Classifications

• A61P9/00

  Drugs for disorders of the cardiovascular system · CPC title

• A61P31/16

  for influenza or rhinoviruses · CPC title

• A61P31/12

  Antivirals · CPC title

• A61P31/14

  for RNA viruses · CPC title

• A61P31/20

  for DNA viruses · CPC title